Ventavis FDA Approval History
FDA Approved: Yes (First approved December 29, 2004)
Brand name: Ventavis
Generic name: iloprost
Dosage form: Inhalation Solution
Company: Johnson & Johnson Innovative Medicine
Treatment for: Pulmonary Arterial Hypertension
Ventavis (iloprost) inhalation solution is synthetic analogue of prostacyclin PGIB2B indicated for the treatment of pulmonary arterial hypertension.
Development timeline for Ventavis
| Date | Article |
|---|---|
| Dec 29, 2004 | Approval Ventavis CoTherix, Inc. - Treatment for Pulmonary Arterial Hypertension |
| Sep 8, 2004 | CoTherix, Inc. Announces Priority Review Designation by the FDA for Ventavis NDA |
| Jul 1, 2004 | CoTherix, Inc. Announces Filing of Ventavis NDA |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.